Novartis Signs Up to $3.2 Billion Deal with Alteogen for Drug-Delivery Technology

Novartis has entered a major agreement with South Korean biotechnology company Alteogen, with the deal potentially reaching $3.2 billion, to gain access to Alteogen’s innovative drug-delivery technology.

The agreement focuses on technology designed to facilitate the development of subcutaneous formulations of medicines that are traditionally administered intravenously. Such technology could potentially make certain treatments more convenient for patients by reducing the need for intravenous administration in appropriate medicines.

The deal highlights the pharmaceutical industry’s growing focus on drug-delivery innovation, particularly technologies that can improve how complex medicines are administered. Moving suitable therapies from intravenous infusion to injectable formulations could offer greater convenience and potentially simplify treatment delivery.

For Novartis, the partnership strengthens its access to next-generation drug-delivery capabilities, while Alteogen gains an opportunity to expand the application of its technology through collaboration with a major global pharmaceutical company.

The agreement represents another significant step in the industry’s shift toward more patient-friendly drug-delivery solutions and demonstrates the increasing value of advanced formulation technologies in modern pharmaceutical development.